Coeur Mining CDE
$10.68 −$0.86 (-7.45%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $10.93 +2.34%
Open$11.35
Prev close$11.54
Day range$10.60 – $11.57
Volume36.67M
Market cap$10.91B
P/E (TTM)12.4
Dividend yield0.19%
CDE Stock News
Headlines matching Coeur Mining or the CDE ticker, most recent first.
- Tianyu Co., Ltd.: Announcement Regarding the Approval of Its Wholly-Owned Subsidiary's Active Pharmaceutical Ingredient by the CDE Review Positive
- The Center for Drug Evaluation (CDE) has accepted Roche's (RHHBY.US) marketing application for faricimab injection, indicated for the treatment of uveitic macular edema.
- Scotiabank Maintains Coeur Mining(CDE.US) With Buy Rating, Maintains Target Price $26.5
- The product of Guobang Pharma's (605507.SH) subsidiary, glyceryl dicaprylate/dicaprate, has passed the joint review and approval process with the finished dosage form by the Center for Drug Evaluation (CDE). Positive
- Guobang Pharma: Glyceryl Dicocoate, a product of its wholly-owned subsidiary, has passed the joint review and approval process with the finished dosage form by the Center for Drug Evaluation (CDE). Positive
- A Quick Look at Today's Ratings for Coeur Mining(CDE.US), With a Forecast Between $18 to $26.5
- ATB Cormark Capital Markets Downgrades Coeur Mining(CDE.US) to Hold Rating, Cuts Target Price to $18 Negative
- BMO Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $26 Negative
- RBC Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Maintains Target Price $23
- Scotiabank Initiates Coeur Mining(CDE.US) With Buy Rating, Announces Target Price $28.5
- Roth MKM Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $21 Negative
- Scotiabank Maintains Coeur Mining(CDE.US) With Buy Rating, Raises Target Price to $28.5 Positive
- Tianyu Co., Ltd.: Announcement Regarding the Approval of the Company\'s Active Pharmaceutical Ingredient by the CDE Review Positive
- RBC Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $23 Negative
- Tianyu Co., Ltd.: Announcement Regarding the Approval of the Company\'s Active Pharmaceutical Ingredient by the CDE Review Positive
No comments yet — be the first to weigh in on CDE.
Sign in to join the discussion.